Registration successful.
Account activated – Pending validation
Your account has been activated successfully, but we still need to validate you as a UK healthcare professional. We’ll send you an email with the result. Please note this could take up to 10 days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website.
Patients
How do you know which treatment is right for a patient? It can be a tricky question to answer. Below are some patient profiles to help you identify patients that may benefit from GSK’s COPD treatments.
Meet Hannah
Age:
56 years
Presentation:
Recently diagnosed with COPD, struggles with breathlessness despite daily SABA use.
Indication
Anoro Ellipta is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). 4
Meet Sylvia
Presentation:
She is on treatment with an ICS/LABA, symptomatic and at risk of an exacerbation:
- Has worsening of symptoms, or
- Has experienced an exacerbation treated with antibiotics or oral corticosteroids, in the past 12 months.
Could Trelegy▼ Ellipta
(fluticasone furoate / umeclidinium / vilanterol) help?
Indication
Trelegy Ellipta is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an ICS and a LABA, or a combination of a LAMA and a LABA. 3
Studies
The safety and efficacy profile of our COPD treatments have been studied in clinical trials. Do you want to learn more? You can explore the studies here:
Anoro vs. tiotropium 1
Interested in whether dual bronchodilator Anoro Ellipta (UMEC/VI) could improve outcomes for your patients with COPD compared to using tiotropium alone? If so, this pooled post hoc analysis is for you.
Your resources
Benefit from expert opinion and free downloadable resources, including training devices and COPD Assessment Test (CAT) pads.
Watch the experts
You’ll hear how medical experts tackle some of the key issues in COPD management and what this could mean for your patients.
Order the CAT pad
Assess the impact COPD is having on your patients’ lives by using the COPD Assessment Test (CAT).
Free resources
Need an Ellipta training inhaler? Or simply looking for some patient resources on COPD? Then this is the place for you.
Abbreviations
CAT, COPD assessment test; COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroid; LABA, long-acting beta agonist; LAMA, long-acting muscarinic receptor antagonist
Trademarks are the property of their respective owners. Anoro Ellipta and Trelegy Ellipta were developed in collaboration with INNOVIVA
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.
